 The purpose of this study is to assess the safety and tolerability of AG013 genetically modified L. lactis bacteria engineered to secrete human Trefoil Factor 1, and to explore the ability of AG013 to attenuate the course and severity of oral mucositis OM in subjects receiving induction chemotherapy for the treatment of head and neck cancer. 